IncellDx have entered into an pharma partnering agreement with Bristol-Myers Squibb Company to the development of an assay for potential application in a molecular companion diagnostic.
It is intended to identify patients likely to benefit from treatment with a Bristol-Myers Squibb drug that is currently under development.
The test will be based upon a modification of IncellDx's quantitative InCellCept assay.
If successful, the companies anticipate extending their pharma partnering relationship into development of a molecular companion diagnostic in which the assay would be used to determine phenotypic susceptibility of patients' disease prior to treatment.
Financial terms of the agreement were not disclosed.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Bristol-Myers Squibb
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity